IL257956A - New carbohydrate antibodies, pharmaceutical preparations and their uses - Google Patents
New carbohydrate antibodies, pharmaceutical preparations and their usesInfo
- Publication number
- IL257956A IL257956A IL257956A IL25795618A IL257956A IL 257956 A IL257956 A IL 257956A IL 257956 A IL257956 A IL 257956A IL 25795618 A IL25795618 A IL 25795618A IL 257956 A IL257956 A IL 257956A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- novel carbohydrate
- carbohydrate antibodies
- antibodies
- novel
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238680P | 2015-10-07 | 2015-10-07 | |
| PCT/US2016/056032 WO2017062792A1 (en) | 2015-10-07 | 2016-10-07 | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL257956A true IL257956A (en) | 2018-06-28 |
Family
ID=58488607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257956A IL257956A (en) | 2015-10-07 | 2018-03-07 | New carbohydrate antibodies, pharmaceutical preparations and their uses |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10501532B2 (OSRAM) |
| EP (1) | EP3359193A4 (OSRAM) |
| JP (1) | JP2018536628A (OSRAM) |
| KR (1) | KR20180077181A (OSRAM) |
| CN (1) | CN108472362B (OSRAM) |
| AR (1) | AR106307A1 (OSRAM) |
| AU (1) | AU2016335842A1 (OSRAM) |
| BR (1) | BR112018006140A2 (OSRAM) |
| CA (1) | CA3000531A1 (OSRAM) |
| IL (1) | IL257956A (OSRAM) |
| TW (1) | TWI704159B (OSRAM) |
| WO (1) | WO2017062792A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6431920B2 (ja) | 2013-09-17 | 2018-11-28 | オービーアイ ファーマ，インコーポレイテッド | 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 |
| JP2018532990A (ja) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ，インコーポレイテッド | グリカンアレイおよび使用の方法 |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| MY200886A (en) | 2016-04-22 | 2024-01-22 | Obi Pharma Inc | Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens |
| JP2019527690A (ja) | 2016-07-27 | 2019-10-03 | オービーアイ ファーマ，インコーポレイテッド | 免疫原性／治療用グリカン組成物およびその使用 |
| US11643456B2 (en) | 2016-07-29 | 2023-05-09 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
| TWI767959B (zh) * | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| CA3064443A1 (en) * | 2017-05-24 | 2018-11-29 | Development Center For Biotechnology | Humanized antibodies against globo h and uses thereof in cancer treatments |
| MX2020009468A (es) * | 2018-03-13 | 2020-10-22 | Hoffmann La Roche | Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20. |
| TW202016147A (zh) * | 2018-06-01 | 2020-05-01 | 台灣浩鼎生技股份有限公司 | 使用抗Globo H或抗SSEA-4抗體與抗負面免疫檢查點抗體之結合醫療 |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| CN116589572B (zh) * | 2023-06-28 | 2023-11-10 | 湖南诺合新生物科技有限公司 | 一种抗ha标签的单克隆抗体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| EP1646655A2 (en) | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| EP1848672A4 (en) * | 2005-02-01 | 2009-11-04 | Morphosys Ag | LIBRARIES AND METHOD FOR ISOLATING ANTIBODIES |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| TWI392502B (zh) * | 2009-06-16 | 2013-04-11 | Academia Sinica | 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗 |
| WO2011136911A2 (en) | 2010-04-09 | 2011-11-03 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| WO2013006449A2 (en) | 2011-07-01 | 2013-01-10 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| WO2015015629A1 (ja) | 2013-08-02 | 2015-02-05 | 株式会社日立製作所 | 炭化珪素半導体装置および炭化珪素半導体装置の製造方法 |
| CN104693305A (zh) * | 2013-12-04 | 2015-06-10 | 苏州中赢医疗科技有限公司 | 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用 |
| WO2015143126A1 (en) * | 2014-03-19 | 2015-09-24 | Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
| SG11201607258SA (en) | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
-
2016
- 2016-10-07 CA CA3000531A patent/CA3000531A1/en not_active Abandoned
- 2016-10-07 AU AU2016335842A patent/AU2016335842A1/en not_active Abandoned
- 2016-10-07 KR KR1020187012974A patent/KR20180077181A/ko not_active Withdrawn
- 2016-10-07 AR ARP160103089A patent/AR106307A1/es unknown
- 2016-10-07 TW TW105132620A patent/TWI704159B/zh active
- 2016-10-07 BR BR112018006140A patent/BR112018006140A2/pt not_active IP Right Cessation
- 2016-10-07 EP EP16854440.1A patent/EP3359193A4/en not_active Withdrawn
- 2016-10-07 JP JP2018516418A patent/JP2018536628A/ja active Pending
- 2016-10-07 WO PCT/US2016/056032 patent/WO2017062792A1/en not_active Ceased
- 2016-10-07 US US15/288,562 patent/US10501532B2/en active Active
- 2016-10-07 CN CN201680056209.7A patent/CN108472362B/zh active Active
-
2018
- 2018-03-07 IL IL257956A patent/IL257956A/en unknown
-
2019
- 2019-08-21 US US16/547,009 patent/US11236154B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180077181A (ko) | 2018-07-06 |
| TWI704159B (zh) | 2020-09-11 |
| CN108472362B (zh) | 2022-03-29 |
| EP3359193A4 (en) | 2019-05-08 |
| AU2016335842A1 (en) | 2018-04-12 |
| BR112018006140A2 (pt) | 2018-10-23 |
| WO2017062792A1 (en) | 2017-04-13 |
| TW201718658A (zh) | 2017-06-01 |
| AR106307A1 (es) | 2018-01-03 |
| US11236154B2 (en) | 2022-02-01 |
| US20200048334A1 (en) | 2020-02-13 |
| CA3000531A1 (en) | 2017-04-13 |
| HK1256414A1 (zh) | 2019-09-20 |
| JP2018536628A (ja) | 2018-12-13 |
| EP3359193A1 (en) | 2018-08-15 |
| US20170101462A1 (en) | 2017-04-13 |
| US10501532B2 (en) | 2019-12-10 |
| CN108472362A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276695B (en) | Antibodies, pharmaceutical preparations and their uses | |
| ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
| IL268588A (en) | Anti-gprc5d antibodies, compositions comprising same and uses thereof | |
| IL257956A (en) | New carbohydrate antibodies, pharmaceutical preparations and their uses | |
| IL262497A (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| ZA201701168B (en) | Antibodies, compositions, and uses | |
| DK3297605T3 (da) | Topiske, farmaceutiske sammesætninger | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| IL247100A0 (en) | Antibodies against cd84, preparations containing them and their uses | |
| PT3223796T (pt) | Composições farmacêuticas, preparação e suas utilizações | |
| IL237852A0 (en) | Antibodies against amphigoline, medical preparations containing them and their use | |
| GB201712159D0 (en) | Pharmaceutical composition | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| HUE068810T2 (hu) | Gyógyászati készítmény | |
| PL3229843T3 (pl) | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji | |
| GB201719447D0 (en) | Pharmaceutical composition | |
| IL258977B (en) | Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them | |
| IL262929B1 (en) | Preparations for treatment, methods of their preparation and their uses | |
| IL255042A0 (en) | Amphiphilic compounds, their preparations and uses | |
| GB201708328D0 (en) | Pharmaceutical composition | |
| GB201708329D0 (en) | Pharmaceutical composition | |
| GB201705661D0 (en) | Pharmaceutical composition | |
| AU2015902960A0 (en) | Compositions, materials and uses thereof | |
| TH1501007100A (th) | องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน | |
| GB201516183D0 (en) | Novel pharmaceutical composition |